Track topics on Twitter Track topics that are important to you
Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment articles that have been published worldwide.
We have published hundreds of Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment news stories on BioPortfolio along with dozens of Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment Clinical Trials and PubMed Articles about Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment Companies in our database. You can also find out about relevant Aortic Valve Valve Externally Mounted Bioprosthesis Safe Treatment Drugs and Medications on this site too.
The St. Jude Medical Trifecta bioprosthesis is a bovine pericardial valve mounted on a titanium stent. The objective of this study was to report a single center experience with the Trifecta aortic valve.
Over the last decade, aortic valve replacement with rapid-deployment biological bioprosthesis has become a common alternative technique to mechanical or biological stented valves for high-risk patients. A 63 year old patient underwent uncomplicated valve replacement with the Edwards Intuity valve. 2 months post operation, the patient had progredient dyspnea. Echocardiography showed a dislocated aortic valve reaching into the left ventricular outflow tract, impairing the anterior mitral valve leaflet. Both v...
The aim of this study was to assess the safety and effectiveness of valve in valve (VIV) TAVI with the autoexpandable valve, specifically in patients with failed Mitroflow (MF) bioprosthetic aortic valves.
Transcatheter aortic valve implantation (TAVI) has emerged as a less invasive treatment than surgical aortic valve replacement in patients with aortic stenosis. Understanding the anatomy of aortic valve complex may help in optimal positioning of prosthetic valve and circumvent complications that can arise during its implantation.
The objective of this study was to determine whether valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) is associated with better survival than redo surgical aortic valve replacement (SAVR) in patients with degenerated aortic valve bioprostheses, and we performed a meta-analysis of comparative studies.
Transcatheter aortic valve replacement (TAVR) is not currently approved for pure native valve aortic incompetence, and is typically performed on a compassionate basis in selected patients who are at high risk for conventional surgery. We describe the first use of TAVR to treat iatrogenic severe acute pure aortic incompetence following mitral valve surgery. A 71-year-old gentleman developed life-threatening acute aortic regurgitation (AR) within hours of a very challenging fifth open heart mitral valve repla...
To analyze the behavior of platelets after transcatheter valve-in-valve implantation for the treatment of degenerated bioprosthesis and how they correlate with adverse events upon follow-up.
Quadricuspid aortic valves are rare congenital malformations. Although aortic valve replacement is the first-choice treatment in most cases, aortic valve repair using a tricuspidization procedure has been reported. Herein, we report the case of a patient with a quadricuspid aortic valve associated with aortic insufficiency that we successfully repaired with aortic valve-sparing root replacement and bicuspidization.
The aim of this study was to evaluate outcomes of valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) in patients with degenerated small bioprostheses.
A 70-year-old woman with substernal chest pain lasting 2.5 h presented to the emergency department of our hospital. She had a history of aortic valve replacement with the Freestyle stentless aortic bioprosthesis for severe aortic regurgitation 7 years ago. The initial electrocardiogram showed sinus rhythm at a rate of 71 bpm with ST-segment slight elevation in leads II, III and aVF. She was diagnosed as having acute coronary syndrome and was referred for an urgent catheterization. Urgent coronary angiogra...
Treatment of aortic valve stenosis has been changing since the introduction of transcatheter aortic valve replacement (TAVR). The present study investigates the treatment of aortic valve stenosis in a real-world population 2014 and 2015 in Germany.
Transcatheter aortic valve replacement (TAVR) has become the cornerstone for aortic valve intervention since the first implantation in 2002. Recent advances with novel devices and introduction into lower risk cohorts have been successful. In this review, we discuss the ongoing limitations to transcatheter aortic valve therapy and whether it will replace surgical aortic valve replacement in the foreseeable future.
Structural valve deterioration represents the most important concern regarding the implantation of a biological heart valve in young patients. Several strategies have been proposed to improve prosthesis design in order to optimize performance and durability. Here we describe an early and specific mode for valve degeneration of prosthesis with outwards mounted pericardial leaflets due to pannus overgrowth on the aortic side. This led to leaflet retraction in two consecutive cases four and six years after the...
A major limitation of the more widespread application of aortic valve reconstruction is the lack of a common framework for valve assessment that could be used to guide a standardized approach to aortic valve repair, similar to that used in reconstructive mitral valve surgery. Most patients with a regurgitant aortic valve are young and possess a specific subtype of a bicuspid aortic valve according to the Sievers classifications system. This video tutorial presents the technical aspects of a standardized ...
Bioprosthetic valves are now used for the majority of surgical aortic valve replacements and for all transcatheter aortic valve replacements. However, bioprostheses are subject to structural valve deterioration (SVD) and have, therefore limited durability.
Reconstructive surgery of the aortic valve is being increasingly used in patients with aortic regurgitation and/or aortic aneurysm. Its success depends on restoring normal aortic valve and root form. Echocardiography is the most reliable and precise imaging technique because it defines abnormal morphology and function, essential for selecting appropriate substrates and guiding the surgical strategy. Despite technical advances in echocardiography, aortic valve and aortic root morphology and function are stil...
Aortopathy is common in patients with bicuspid aortic valve (BAV).
We investigated the outcomes of patients who underwent Transcatheter Aortic Valve Replacement (TAVR) with and without Balloon Aortic Valvuloplasty (BAV) using the SAPIEN 3 (S3) valve.
The aim of this study was to assess the commissural alignment between bioprosthetic and native aortic valve leaflets following surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) and to investigate its impact on valvular function and coronary filling.
Several indications for sutureless aortic valve replacement (SU-AVR) have been a matter of debate. We evaluated our experience with Perceval-S (LivaNova group, Saluggia, Italy) SU-AVR in patients with severe aortic stenosis (AS) involving bicuspid aortic valve (BAV), even though presence of BAV is still considered to be a contraindication for sutureless valves.
Unicuspid and bicuspid aortic valve (BAV) are congenital cardiac anomalies associated with valvular dysfunction and aortopathies occurring at a young age.
Transcatheter aortic valve replacement (TAVR) is a recent and an effective treatment option for high- or extreme-surgical-risk patients with symptomatic severe aortic stenosis. However, pure severe native aortic valve regurgitation (NAVR) without aortic stenosis remains a contraindication to TAVR. The aim of our systemic review analysis was to evaluate TAVR in patients with pure NAVR.
A 83-year-old female with severe aortic regurgitation (AR) and an horizontal ascending aorta was scheduled for a transcatheter aortic valve replacement. After the complete deployment, a Portico 29 mm valve embolized in the ascending aorta due to the unfavorable anatomy of the anchoring zone. A second Portico 29 mm was successfully implanted using the embolized valve for superior anchoring. The patient died 7 days after the procedure due to a retrograde aortic dissection. This case shows a rare but pos...
This study sought to evaluate the trends in isolated surgical aortic valve replacement (SAVR) procedures across hospitals with different transcatheter aortic valve replacement (TAVR) volumes among Medicare beneficiaries.